Skip to main content
Journal cover image

PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS

Publication ,  Conference
Peters, K; Kirkpatrick, J; Batinic-Haberle, I; Affronti, M; Woodring, S; Iden, D; Panta, S; Lipp, E; Healy, P; Herndon, J; Spasojevic, I ...
Published in: NEURO-ONCOLOGY
November 5, 2018

ACTR-28

Duke Scholars

Published In

NEURO-ONCOLOGY

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 5, 2018

Volume

20

Issue

suppl. 6; abstr QOLP-13

Start / End Page

1vi7 / vi17

Location

New Orleans, LA

Publisher

OXFORD UNIV PRESS INC

Conference Name

23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Peters, K., Kirkpatrick, J., Batinic-Haberle, I., Affronti, M., Woodring, S., Iden, D., … Crapo, J. (2018). PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. In NEURO-ONCOLOGY (Vol. 20, pp. 1vi7-vi17). New Orleans, LA: OXFORD UNIV PRESS INC. https://doi.org/10.1093/neuonc/noy148.061
Peters, Katherine, John Kirkpatrick, Ines Batinic-Haberle, Mary Affronti, Sarah Woodring, Deborah Iden, Sujata Panta, et al. “PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS.” In NEURO-ONCOLOGY, 20:1vi7-vi17. OXFORD UNIV PRESS INC, 2018. https://doi.org/10.1093/neuonc/noy148.061.
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, et al. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 1vi7-vi17.
Peters, Katherine, et al. “PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS.” NEURO-ONCOLOGY, vol. 20, no. suppl. 6; abstr QOLP-13, OXFORD UNIV PRESS INC, 2018, pp. 1vi7-vi17. Manual, doi:10.1093/neuonc/noy148.061.
Peters K, Kirkpatrick J, Batinic-Haberle I, Affronti M, Woodring S, Iden D, Panta S, Lipp E, Healy P, Herndon J, Spasojevic I, Penchev S, Gad S, Siberstein D, Johnson M, Randazzo D, Desjardins A, Friedman H, Ashley D, Crapo J. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 1vi7-vi17.
Journal cover image

Published In

NEURO-ONCOLOGY

DOI

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 5, 2018

Volume

20

Issue

suppl. 6; abstr QOLP-13

Start / End Page

1vi7 / vi17

Location

New Orleans, LA

Publisher

OXFORD UNIV PRESS INC

Conference Name

23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1109 Neurosciences